Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Double Blind Cross-Over Study of Monarsen (EN101) in Myasthenia Gravis
2005-002740-26Phase 2Completed
- Sponsor
- Ester Neuroscience
- Start
- Dec 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BL-7040 in myasthenia gravis (MG) (3 arms), sponsored by Ester Neuroscience. Primary endpoint: Efficacy (QMG score change). Started Dec 2005; status: completed.
02
Drugs
BL-7040
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2005-002740-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002740-26.